AKT1 and glioblastoma: BET inhibitors, including JQ1, I-BET151, and OTX015, have been shown to exert antitumor effects in GBM by targeting signaling pathways such as VEGF/PI3 K/AKT, and disrupting the coactivation transcriptional program of E2 F1 and BET proteins in GBM cells [132–134].